Guidelines: Difference between revisions
Jump to navigation
Jump to search
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| (26 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
==== Prostate ==== | ==== Prostate ==== | ||
* [[Advanced Prostate Cancer ( | * '''<span style="color:#008000">NEW!</span>''' [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]] | ||
* [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]] | |||
*[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]] | *[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]] | ||
*[[AUA & ASTRO & SUO: Clinically Localized Prostate Cancer (2022)|Clinically Localized Prostate Cancer (2022)]] | *[[AUA & ASTRO & SUO: Clinically Localized Prostate Cancer (2022)|Clinically Localized Prostate Cancer (2022)]] | ||
| Line 14: | Line 15: | ||
==== Bladder ==== | ==== Bladder ==== | ||
* [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer ( | * '''<span style="color:#008000">NEW!</span>''' [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2024 AUA)|Non-muscle Invasive Bladder Cancer (2024)]] | ||
* '''<span style="color:#008000">NEW!</span>''' [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2024)|Muscle-invasive Bladder Cancer (2024)]] | |||
*[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]] | *[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]] | ||
*[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]] | *[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]] | ||
*[[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2020)|Muscle-invasive Bladder Cancer (2020)]] | |||
* [[Muscle-invasive Bladder Cancer (2017)]] | * [[Muscle-invasive Bladder Cancer (2017)]] | ||
* [[CUA/AUA: Non-muscle Invasive Bladder Cancer (2021 CUA/2016 AUA))|Non-muscle Invasive Bladder Cancer (2016)]] | * [[CUA/AUA: Non-muscle Invasive Bladder Cancer (2021 CUA/2016 AUA))|Non-muscle Invasive Bladder Cancer (2016)]] | ||
| Line 35: | Line 38: | ||
==== Andrology ==== | ==== Andrology ==== | ||
* | * [[Priapism|Priapism (2021)]] | ||
*[[Testosterone Deficiency (2018)]] | *[[Testosterone Deficiency (2018)]] | ||
* [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]] | * [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]] | ||
| Line 42: | Line 45: | ||
==== Functional ==== | ==== Functional ==== | ||
* | * [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]] | ||
*[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]] | *[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]] | ||
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]] | *'''<span style="color:#008000">NEW!</span>''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]] | ||
| Line 50: | Line 53: | ||
==== Infertility ==== | ==== Infertility ==== | ||
* | * AUA/ASRM Infertility (2020) included in Chapter Notes of | ||
** [[Infertility: Diagnosis and Evaluation|Diagnosis and Evaluation of Infertility]] | ** [[Infertility: Diagnosis and Evaluation|Diagnosis and Evaluation of Infertility]] | ||
** [[Infertility: Management|Management of Infertility]] | ** [[Infertility: Management|Management of Infertility]] | ||
| Line 59: | Line 62: | ||
==== Pediatrics ==== | ==== Pediatrics ==== | ||
* | *[[AUA: Cryptorchidism (2018)|Cryptorchidism (2018)]] | ||
*[[AUA: Vesicoureteral Reflux (2017)|Vesicoureteral Reflux (2017)]] | *[[AUA: Vesicoureteral Reflux (2017)|Vesicoureteral Reflux (2017)]] | ||
| Line 69: | Line 72: | ||
==== Other ==== | ==== Other ==== | ||
* '''<span style="color:#008000">NEW!</span>''' [[AUA: | * [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]] | ||
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]] | |||
*[[AUA: Urotrauma (2020)|Urotrauma (2020)]] | *[[AUA: Urotrauma (2020)|Urotrauma (2020)]] | ||
* [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]] | * [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]] | ||
| Line 76: | Line 80: | ||
==== Contribute ==== | ==== Contribute ==== | ||
* | * Overactive Bladder (2024) | ||
* | *Incontinence after Prostate Therapy (2024 Amendment) | ||
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024) | *Non-muscle Invasive Bladder Cancer (2024 Amendment) | ||
* | *Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment) | ||
*Neurogenic LUTD (2021) | *Management of LUTS attributed to BPH (2023 Amendment) | ||
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]] | |||
*Disorders of ejaculation (2020) | *Disorders of ejaculation (2020) | ||
* Antibiotic Prophylaxis (2019) | * Antibiotic Prophylaxis (2019) | ||
| Line 168: | Line 173: | ||
* Pheochromocytoma surveillance (2019) | * Pheochromocytoma surveillance (2019) | ||
* Pediatric hemorrhagic cystitis (2019) | * Pediatric hemorrhagic cystitis (2019) | ||
== Other Guidelines == | |||
=== '''<span style="color:#008000">NEW!</span>''' [[EAU & ASCO: Penile Cancer 2023|Penile Cancer (EAU/ASCO 2023)]] === | |||
Latest revision as of 10:14, 19 November 2024
AUA Guidelines[edit | edit source]
Oncology[edit | edit source]
Prostate[edit | edit source]
- NEW! Salvage Therapy for Prostate Cancer (2024)
- Advanced Prostate Cancer (2023)
- Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)
- Clinically Localized Prostate Cancer (2022)
- Adjuvant and Salvage Radiotherapy After Prostatectomy (2019)
- Early Detection of Prostate Cancer/Prostate Cancer Screening (2018)
- Clinically Localized Prostate Cancer (2017)
Bladder[edit | edit source]
- NEW! Non-muscle Invasive Bladder Cancer (2024)
- NEW! Muscle-invasive Bladder Cancer (2024)
- Non-muscle Invasive Bladder Cancer (2020)
- Microscopic Hematuria (2020)
- Muscle-invasive Bladder Cancer (2020)
- Muscle-invasive Bladder Cancer (2017)
- Non-muscle Invasive Bladder Cancer (2016)
Kidney[edit | edit source]
Testicular[edit | edit source]
- (2019) Included in Testicular Tumours Chapter Notes
Upper Tract Urothelial Carcinoma[edit | edit source]
Non-oncology[edit | edit source]
Andrology[edit | edit source]
- Priapism (2021)
- Testosterone Deficiency (2018)
- Erectile Dysfunction (2018)
- Peyronie's Disease (2015)
Functional[edit | edit source]
- Female Stress Urinary Incontinence (2023)
- Management of LUTS Attributed to BPH (2021)
- NEW! Overactive Bladder (2019)
- AUA/CUA Mesh Position Statement (2019)
- Incontinence after Prostate Therapy (2019)
Infertility[edit | edit source]
- AUA/ASRM Infertility (2020) included in Chapter Notes of
Infections and Inflammation[edit | edit source]
Pediatrics[edit | edit source]
Stones[edit | edit source]
Other[edit | edit source]
- Urethral Stricture Disease (2023)
- NEW! Interstitial Cystitis/Bladder Pain Syndrome (2022)
- Urotrauma (2020)
- Male Urethral Stricture (2016)
- Vasectomy (2015)
Contribute[edit | edit source]
- Overactive Bladder (2024)
- Incontinence after Prostate Therapy (2024 Amendment)
- Non-muscle Invasive Bladder Cancer (2024 Amendment)
- Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
- Management of LUTS attributed to BPH (2023 Amendment)
- Neurogenic LUTD (2021)
- Disorders of ejaculation (2020)
- Antibiotic Prophylaxis (2019)
CUA Guidelines[edit | edit source]
Oncology[edit | edit source]
Prostate[edit | edit source]
- Castrate-resistant Prostate Cancer (2021)
- Androgen Deprivation Therapy: Adverse Events & Management (2021)
- Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)
- Testosterone Suppression (2018)
- Prostate Cancer Screening (2017)
- Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017)
- Prostate Cancer Active Surveillance (2015)
Bladder[edit | edit source]
- Non-muscle Invasive Bladder Cancer (2021)
- Advanced and Metastatic Urothelial Cancer (2019)
- Muscle-invasive Bladder Cancer (2019)
- Asymptomatic Microscopic Hematuria (2008)
Kidney[edit | edit source]
- Follow-up Localized RCC (2018)
- Cystic Renal Lesions (2017)
- Small Renal Masses (2015)
- Surgical Management of RCC (2014)
- RCC Genetic Screening (2013)
Non-oncology[edit | edit source]
Andrology[edit | edit source]
Functional[edit | edit source]
- Neurogenic Lower Urinary Tract Dysfunction (2019)
- Male LUTS/BPH (2018)
- CUA/AUA Mesh Position Statement (2019)
- Overactive Bladder (2017)
Infections and Inflammation[edit | edit source]
- CUA/AUA Recurrent UTI (2019)
- Antibiotic Prophylaxis (2015)
- Chronic Scrotal Pain (2018)
- Interstitial Cystitis (2016)
Infertility[edit | edit source]
Pediatrics[edit | edit source]
- Circumcision (2018)
- Antenatal hydronephrosis (2017)
- Cryptorchidism (2017)
- Multicystic Dysplastic Kidney in the Neonate (2015)
Stones[edit | edit source]
Other[edit | edit source]
- Vasectomy (2022)
- Adrenal Mass (2011)
- Radiation-induced Hemorrhagic Cystitis (2018)
- VTE Prophylaxis (2019)
- Vasectomy (2016)
Contribute[edit | edit source]
- Ureteral calculi (2022)
- Pediatric bladder dysfunction (2021)
- Sporadic angiomyolipomas (2020)
- Male urethral stricture (2020)
- Catheter use (2020)
- Renal mass biopsy (2019)
- Pheochromocytoma surveillance (2019)
- Pediatric hemorrhagic cystitis (2019)